DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology supportive care products, announced today that it has granted T3D Therapeutics, Inc. the exclusive worldwide rights to develop and commercialize DB959. DB959 is an oral, highly selective, dual nuclear receptor agonist whose primary target is PPARδ
(peroxisome proliferator activated receptor delta). DARA had previously developed DB959 through Phase 1 clinical trials for the treatment of diabetes and dyslipidemia.
(919) 237-4897
info@t3dtherapeutics.com
